Scotia Capital Inc. Increases Stock Position in BioNTech SE (NASDAQ:BNTX)

Scotia Capital Inc. raised its position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 20.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 175,224 shares of the company's stock after buying an additional 30,143 shares during the period. Scotia Capital Inc. owned about 0.07% of BioNTech worth $19,967,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in BNTX. CenterBook Partners LP lifted its position in BioNTech by 62.5% in the fourth quarter. CenterBook Partners LP now owns 194,118 shares of the company's stock valued at $22,120,000 after acquiring an additional 74,656 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in BioNTech during the 4th quarter worth about $584,000. APG Asset Management N.V. purchased a new position in shares of BioNTech during the 4th quarter worth about $5,161,000. Legal & General Group Plc increased its position in BioNTech by 16.0% during the 4th quarter. Legal & General Group Plc now owns 247,501 shares of the company's stock worth $27,938,000 after purchasing an additional 34,226 shares in the last quarter. Finally, FMR LLC raised its stake in shares of BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after acquiring an additional 1,401,547 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BNTX shares. Canaccord Genuity Group restated a "buy" rating and set a $171.44 target price on shares of BioNTech in a research note on Tuesday, March 11th. Citigroup started coverage on BioNTech in a research report on Thursday, March 13th. They set a "buy" rating and a $145.00 price target on the stock. Morgan Stanley cut their price target on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a report on Tuesday, March 11th. Truist Financial initiated coverage on shares of BioNTech in a research report on Friday, January 10th. They issued a "buy" rating and a $172.00 target price for the company. Finally, HC Wainwright lowered their price objective on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $143.44.

Remove Ads

BioNTech Trading Down 0.2 %

Shares of NASDAQ BNTX traded down $0.16 during midday trading on Wednesday, hitting $98.84. 213,632 shares of the company traded hands, compared to its average volume of 857,703. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The firm has a market cap of $23.72 billion, a P/E ratio of -47.07 and a beta of 1.07. The stock has a 50-day moving average price of $103.82 and a 200 day moving average price of $111.43.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech's revenue for the quarter was down 19.5% on a year-over-year basis. During the same period last year, the company earned $1.90 EPS. As a group, analysts expect that BioNTech SE will post -3.88 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.